ICYMI: Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24. https://t.co/o2b1kwZ9QG https://t.co/ayaDlpl7DI